cancers-logo

Journal Browser

Journal Browser

Translational Research and Clinical Trials in Gastric Cancer: Advances and Future Directions

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research in Cancer".

Deadline for manuscript submissions: 15 November 2026 | Viewed by 720

Editor


E-Mail Website
Guest Editor
Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA
Interests: gastric cancer; peritoneal carcinomatosis; robotic surgery; surgical innovation; immune biomarkers; early detection

Special Issue Information

Dear Colleagues,

Gastric cancer remains a leading cause of global cancer mortality, with substantial regional variation in stage at diagnosis, access to specialized surgery and integration of systemic therapy. While Japan and South Korea have established standardized D2 lymphadenectomy and early detection pathways, many regions continue to manage locally advanced and metastatic disease in heterogeneous care settings. Rapid advances in perioperative therapy, immunotherapy integration, surgical technology and biologic stratification underscore the need to align translational discoveries with well-designed clinical trials.

This issue will highlight cutting-edge laboratory insights and practice-changing clinical investigations across the spectrum of disease:

  1. Biologic rationale for treatment sequencing—neoadjuvant/perioperative therapy (e.g., FLOT ± durvalumab) versus upfront surgery
  2. Translational correlates of response and resistance, including tumor regression grading and biomarker-driven strategies
  3. Impact of modern systemic therapy on surgical complexity and outcomes, including fibrosis and operative time
  4. Prospective evaluation of minimally invasive and robotic gastrectomy in the post-neoadjuvant setting
  5. Role of staging laparoscopy and novel detection methods for occult peritoneal metastases
  6. Clinical trials in conversion therapy, including peritoneal-directed approaches for carcinomatosis and liver-directed therapy or hepatectomy for oligometastatic disease
  7. Molecular profiling and immunotherapy integration in localized and metastatic disease
  8. Centralization, surgical quality metrics and global trial harmonization

Together, these topics emphasize the bidirectional integration of translational science and clinical trial innovation to advance precision, multidisciplinary gastric cancer care.

Dr. Yanghee Woo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • multidisciplinary management
  • conversion gastrectomy
  • molecular biomarker testing
  • diagnostic laparoscopy
  • neoadjuvant therapy
  • upfront surgery
  • intraperitoneal treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 5316 KB  
Review
Hemorrhagic Complications in Gastric Cancer: Current Evidence and Multidisciplinary Management Strategies
by Sang-Ho Jeong, Miyeong Park, Kyung Won Seo and Jae-Seok Min
Cancers 2026, 18(15), 2430; https://doi.org/10.3390/cancers18152430 - 28 Jul 2026
Viewed by 498
Abstract
Hemorrhage is a clinically important emergency in gastric cancer, occurring in an estimated 3–36% of patients (with the incidence varying substantially by disease stage, tumor morphology, and the operational definition of hemorrhage applied), and potentially becoming life-threatening within 24 h. This review synthesizes [...] Read more.
Hemorrhage is a clinically important emergency in gastric cancer, occurring in an estimated 3–36% of patients (with the incidence varying substantially by disease stage, tumor morphology, and the operational definition of hemorrhage applied), and potentially becoming life-threatening within 24 h. This review synthesizes evidence from the past two decades to propose a multidisciplinary, stepwise framework for managing gastric cancer-associated bleeding. Endoscopic hemostasis remains the first-line intervention and achieves initial bleeding control in 83–92.9% of cases, although 30-day rebleeding occurs in up to 28–41%. Transcatheter arterial embolization is an important option for persistent bleeding or hemodynamic instability, with a reported clinical success of approximately 72%. Palliative radiotherapy provides effective hemostasis in 68–88.5% of cases, and a biologically effective dose (BED10) exceeding 39 Gy may improve bleeding control. Surgery should be individualized according to disease stage, resectability, physiological reserve, and treatment intent, ranging from emergency vessel ligation to curative resection. Importantly, hemostasis should be regarded not as a final endpoint but as a therapeutic bridge enabling definitive anticancer therapy. Successful bleeding control followed by systemic chemotherapy is associated with improved overall survival. Management therefore requires coordinated decision-making among gastroenterology, interventional radiology, surgery, radiation oncology, and medical oncology teams. Full article
Show Figures

Figure 1

Back to TopTop